我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

不同剂量替罗非班联合替格瑞洛对NSTEMI患者短期心血管事件及血小板聚集率的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2017年第4期
页码:
427-430
栏目:
临床研究
出版日期:
2017-02-25

文章信息/Info

Title:
Effect of different doses of terofiban combined with ticagrelor on short-term cardiovascular events and platelet aggregation rate in patients with non-ST-elevation myocardial infarction
作者:
陆 胜; 余再新; 黄友良; 谭碧峰
中南大学湘雅医院心内科，湖南 长沙 418000
Author(s):
LU Sheng;  YU Zai-xin;  HUANG You-liang;  TAN Bi-feng
Department of Cardiology, Xiangya Hospital, Central South University, Changsha 418000, Hunan, China
关键词:
心肌梗死; 非ST段抬高型; 急性; 替罗非班; 替格瑞洛; 血小板聚集; 心血管事件
Keywords:
non-ST-elevation myocardial infarction;  terofiban;  ticagrelor;  platelet aggregation;  cardiovascular events;  analysis
分类号:
R541.4
DOI:
-
文献标识码:
A
摘要:
目的 探讨不同剂量替罗非班联合替格瑞洛对急性非ST段抬高型心肌梗死（NSTEMI）患者短期心血管事件及血小板聚集率的影响。方法 收集128例NSTEMI患者，根据不同用药方式分为替格瑞洛组（A组，n=39）、常规剂量替罗非班联合替格瑞洛组（B组，n=46）和小剂量替罗非班联合替格瑞洛组（C组，n=41）。治疗4周后，比较3组患者的血小板聚集率、血纤维蛋白原（Fib）水平以及心血管事件、不良反应发生率。结果 治疗4周后，A组复合项终点事件发生率明显高于B组和C组，差异有统计学意义（P<0.05）；治疗1、4周后，B组和C组血小板聚集率、血Fib水平均显著低于A组，差异有统计学意义（P<0.05），B组和C组血小板聚集率、血Fib水平比较差异均无统计学意义 ；B组不良反应发生率明显高于A组和C组，差异有统计学意义（P<0.05）。结论 常规剂量和小剂量替罗非班联合替格瑞洛均可减少NSTEMI患者短期心血管事件的发生，增强血小板聚集的抑制作用，且小剂量的替罗非班减少了不良反应的发生。
Abstract:
AIM To investigate the effect of different doses of terofiban combined with ticagrelor on short-term cardiovascular events and platelet aggregation rate in patients with (NSTEMI). METHODS One hundred and twenty-eight NSTEMI patients in our hospital were included in the study. According to different treatment methods, the patients were divided into ticagrelor group (group A, n=39), the conventional dose of tirofiban combined with ticagrelor group (group B, n=46) and small dose of tirofiban combined with Grillo group (group C, n=41). After 4 weeks of treatment, the platelet aggregation rate, fibrinogen (Fib) level and cardiovascular events, and incidence of adverse events were compared between the three groups. RESULTS After 4 weeks of treatment, the occurrence rate of composite endpoint in group A was significantly higher than those in group B and group C (P<0.05). The platelet aggregation rate and blood Fib levels in group B and group C were significantly lower than those in group A (P<0.05). The incidence of adverse reactions in group B was significantly higher than those in group A and group C (P<0.05). CONCLUSION Conventional dose and small dose of tirofiban combined with ticagrelor can reduce short-term cardiovascular events in NSTEMI patients and enhance the inhibition of platelet aggregation. Small dose of tirofiban reduces the incidence of adverse reactions.

参考文献/References

[1]刘辉 ，张 燕，张少利，等.老年非ST段抬高型急性心肌梗死患者临床特征及预后影响因素[J].山东医药,2016,56(11):41-43.
[2]许海燕,姚康宝,顼志敏.首次急性ST段抬高与非ST段抬高心肌梗死患者临床及冠状动脉病变特点比较[J].中华老年心脑血管病杂志,2012,14(4):361-363.
[3]Valgimigli M,Biondi-Zoccai G,Tebaldi M,et al.Tirofiban as adjunctive therapy for acute coronary syndromes and percutaneous coronary intervention:a meta-analysis of randomized trials[J].Eur Heart J,2010,31(1):35-49.
[4]王荣军,王艳英,赵大宇.替罗非班治疗急性非ST段抬高型心肌梗死50例临床观察[J].中国急救医学,2015,35(z2):113-115.
[5]杨晓燕,龚培力,王 琳,等.替罗非班治疗急性冠状动脉综合征的疗效和安全性评价[J].中国医院药学杂志,2006,26(3):275-278.
[6]中华医学会心血管病学分会,中华心血管病杂志编辑委员会.2007中国不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304.
[7]王海艳,朱正炎.急性非ST段抬高心肌梗死冠状动脉病变与临床特点[J].医学综述,2014,20(2):359-361.
[8]周 觉,陈之力,李 勇.不同剂量替罗非班联合替格瑞洛对急性期NSTEMI患者的疗效及血栓抑制作用分析[J].实用药物与临床,2016,19(2):160-163.
[9]栗 喆,顾东风.替格瑞洛对冠心病心绞痛功能抑制的研究[J].现代药物与临床,2014,29(5):508-511.
[10]Storey RF,Becker RC,Harrington RA,et al.Pulmonary function in patients with acute coronary syndrome treated with ticagrelor orclopidogrel(from the Platelet Inhibition and Patient Outcomes[PLATO]pulmonary functionsubstudy)[J].Am J Cardiol,2011,108(11):1542-1546.
[11]李秀芬,葛振嵘,许力舒,等.替格瑞洛联合小剂量替罗非班对急性非ST段抬高心肌梗死患者纤维蛋白原的影响[J].中华老年心脑血管病杂志, 2015, 17(4):429-430.
[12]戴青原,李明阳,杨 萍,等.冠心病患者血浆纤维蛋白原、血栓前体蛋白水平与冠状动脉病变程度的相关性[J].昆明医科大学学报,2015,36(9):113-117.
[13]Pikija S,Trkulja V,Mutzenbach JS,et al.Fibrinogen consumption is related to intracranial clot burden in acute ischemic stroke:a retrospective hyperdense artery study[J].J Transl Med,2016,14(1):250.
[14]Peng Y,Li YM,Chai H,et al.Understanding the controversy surrounding the correlation between fibrinogen level and prognosis of coronary artery disease-The role of the subtypes of coronary artery disease[J].Int J Cardiol,2016,28:968-972.

备注/Memo

备注/Memo:
收稿日期：2016-09-18.通讯作者：余再新，教授，主要从事心脏病介入诊疗研究 Email：zkp2380@163.com 作者简介：陆胜，副主任医师，硕士生 Email：zkp2380@163.com
更新日期/Last Update: 1900-01-01